BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10993130)

  • 1. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
    Venditti LN; Arcelus A; Birnbaum H; Greenberg P; Barr CE; Rowland C; Williamson T
    Int Clin Psychopharmacol; 2000 Sep; 15(5):279-89. PubMed ID: 10993130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
    Dubini A; Bosc M; Polin V
    J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
    Massana J
    J Clin Psychiatry; 1998; 59 Suppl 14():8-10. PubMed ID: 9818624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
    Dubini A; Bosc M; Polin V
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.
    Bosc M; Dubini A; Polin V
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S57-70; discussion S71-3. PubMed ID: 9169311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale.
    Healy D
    Acta Psychiatr Scand Suppl; 2000; 402():45-51. PubMed ID: 10901159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).
    Keller M
    Gen Hosp Psychiatry; 2001; 23(1):15-9. PubMed ID: 11226552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
    Nelson JC; Portera L; Leon AC
    J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of social functioning in depression.
    Bosc M
    Compr Psychiatry; 2000; 41(1):63-9. PubMed ID: 10646621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
    Taner E; Demir EY; Cosar B
    Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chairman's overview. The place of reboxetine in antidepressant therapy.
    Montgomery SA
    J Clin Psychiatry; 1998; 59 Suppl 14():26-9. PubMed ID: 9818628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
    Nelson JC; Portera L; Leon AC
    Biol Psychiatry; 2005 Jun; 57(12):1535-42. PubMed ID: 15953490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
    Massana J; Möller HJ; Burrows GD; Montenegro RM
    Int Clin Psychopharmacol; 1999 Mar; 14(2):73-80. PubMed ID: 10220121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of reboxetine in major depression.
    Schatzberg AF
    J Clin Psychiatry; 2000; 61 Suppl 10():31-8. PubMed ID: 10910015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reboxetine: additional benefits to the depressed patient.
    Montgomery SA
    J Psychopharmacol; 1997; 11(4 Suppl):S9-15. PubMed ID: 9438228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression.
    Kuenzel HE; Murck H; Held K; Ziegenbein M; Steiger A
    Pharmacopsychiatry; 2004 Sep; 37(5):193-5. PubMed ID: 15359374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reboxetine: the first selective noradrenaline re-uptake inhibitor.
    Kasper S; el Giamal N; Hilger E
    Expert Opin Pharmacother; 2000 May; 1(4):771-82. PubMed ID: 11249515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat.
    Johansson D; Falk A; Marcus MM; Svensson TH
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):143-8. PubMed ID: 22691715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.
    Wong EH; Sonders MS; Amara SG; Tinholt PM; Piercey MF; Hoffmann WP; Hyslop DK; Franklin S; Porsolt RD; Bonsignori A; Carfagna N; McArthur RA
    Biol Psychiatry; 2000 May; 47(9):818-29. PubMed ID: 10812041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.